| Biotechnology Industry | Healthcare Sector | - CEO | WSE Exchange | PLSNKTK00019 ISIN |
| Poland Country | 165 Employees | 28 Jan 2026 Last Dividend | - Last Split | - IPO Date |
Synektik S.A. is a leading entity in the medical technology realm, with a major emphasis on the innovation and provision of radiopharmaceuticals and medical equipment. Positioned at the forefront of the healthcare sector, the company excels in crafting groundbreaking solutions tailored for diagnostic imaging and radiation oncology. Through its dedicated efforts, Synektik S.A. significantly enhances the precision of diagnoses and treatments, profoundly impacting patient care efficacy. The company captures a critical market role by responding to the escalating demands for sophisticated diagnostic methods and individualized treatment approaches, mirroring the healthcare industry’s shift towards more directed and efficacious therapies. Synektik S.A.'s steadfast partnerships with healthcare providers and research entities underscore its crucial contribution to the evolution of medical technology and the improvement of patient outcomes globally.
Synektik S.A. specializes in the development and supply of radiopharmaceuticals and isotopes, fundamental for nuclear medicine procedures. These products are used in diagnostic imaging to detect and treat various diseases, enabling physicians to diagnose conditions accurately and decide on the most appropriate treatment plans.
The company distributes advanced medical imaging systems, including MRI and CT scanners, essential for non-invasive diagnostic procedures. These systems play a crucial role in today's healthcare by offering detailed images of the human body, aiding in the early detection and treatment of diseases.
With a focus on improving diagnostic accuracy and treatment precision, Synektik S.A. provides innovative solutions tailored for the fields of diagnostic imaging and radiation oncology. This encompasses a range of products and technologies designed to enhance the effectiveness of patient care, from advanced imaging techniques to targeted radiation therapy options.